Mantle Cell Lymphoma News

TP53 Predicts Poorer Survival in Mantle Cell Lymphoma - OncLive



OncLive
 
TP53 Predicts Poorer Survival in Mantle Cell Lymphoma 
OncLive
?TP53-mutated MCL represents a phenotypically distinct and highly aggressive disease entity with poor or no response to the high-dose regimens including cytarabine, rituximab and [autologous stem-cell transplant],? first author Christian W. Eskelund ...

 


Emerging Agents for Mantle Cell Lymphoma - OncLive



OncLive
 
Emerging Agents for Mantle Cell Lymphoma 
OncLive
Brad S. Kahl, MD: We're looking forward to seeing the results of the acalabrutinib trial in mantle cell lymphoma, and there are other trials that could also have the potential to influence the standard of care. There's a trial called SHINE, which is ...

 


Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma - Pharmacy Today, American Pharmacists Association, pharmacist.com



Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma 
Pharmacy Today, American Pharmacists Association, pharmacist.com
Maintenance therapy with rituximab after autologous stem-cell transplantation extended event-free survival, progression-free survival, and overall survival in patients with mantle-cell lymphoma who were younger than age 66 years at diagnosis, according ...

 


NICE knocks-back Janssen's Imbruvica in mantle cell lymphoma - PharmaTimes



PharmaTimes
 
NICE knocks-back Janssen's Imbruvica in mantle cell lymphoma 
PharmaTimes
In draft guidance NICE has declined to recommend Imbruvica's use in England and Wales to treat mantle cell lymphoma. The Institute said the drug's use for this indication would not be a cost-effective use of NHS resources, despite Janssen having agreed ...
Janssen's Imbruvica runs into trouble with NICE in mantle cell lymphoma pharmaphorum
Price deal sees NICE back Imbruvica for one indication but not another The Pharma Letter (registration)

all 3 news articles » 


Maintenance rituximab prolongs survival for certain patients with ... - Healio



Maintenance rituximab prolongs survival for certain patients with ... 
Healio
Rituximab maintenance therapy after autologous hematopoietic stem cell transplantation prolonged EFS, PFS and OS among patients aged younger than 66 ...
Adding Drug to Standard Care May Prolong Lymphoma Survival ... U.S. News & World Report

all 2 news articles » 


Haematological cancer: Extended EFS with rituximab - Nature.com



Haematological cancer: Extended EFS with rituximab 
Nature.com
Patients with mantle-cell lymphoma (MCL) are commonly treated with a combination regimen comprising rituximab and high-dose cytarabine, followed by autologous stem-cell transplantation (ASCT). In a study led by Steven Le Gouill, post-transplantation ...

 


Rituximab after autologous stem cell transplantation in mantle cell ... - 2 Minute Medicine



2 Minute Medicine
 
Rituximab after autologous stem cell transplantation in mantle cell ... 
2 Minute Medicine
1. Patients with mantle cell lymphoma treated with autologous stem cell transplantation experienced greater overall, event-free, and progression-free survival.

and more » 


Observation After Diagnosis Viable Strategy for Some Patients With MCL - OncLive



OncLive
 
Observation After Diagnosis Viable Strategy for Some Patients With MCL 
OncLive
Some patients with mantle cell lymphoma (MCL) can delay treatment without experiencing negative outcomes, according to findings from a population-based study of patients entered into the British Columbia Cancer Agency Lymphoid Cancer Database from ...

 


Celgene Blood Cancer Treatment: Just A Tip Of Biotech Stock's ... - Investor's Business Daily



Investor's Business Daily
 
Celgene Blood Cancer Treatment: Just A Tip Of Biotech Stock's ... 
Investor's Business Daily
Celgene became a biotech juggernaut thanks to a treatment for tricky blood cancers. Now drugs battling lupus, MS and more are on the stock's potential hit list.

and more » 


Maintenance Rituximab Post-ASCT Associated With Improved OS in MCL - OncLive



OncLive
 
Maintenance Rituximab Post-ASCT Associated With Improved OS in MCL 
OncLive
Patients who received maintenance therapy with rituximab (Rituxan) following autologous stem cell transplantation (ASCT) as treatment for mantle cell lymphoma (MCL) had a survival advantage, according to results from a retrospective single-center study.